In lung cancer patients, CMTM6 acts as a predictor for programmed cell death 1 (PD-1) inhibitor therapy; i.e., patients with higher CMTM6 expression respond well to PD-1 inhibitors (16, 17). Here, PDCD1 is linked to lung carcinoma.